These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2633 related items for PubMed ID: 19573383

  • 1. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L, Luo XP, Du ML, Ma HM, Gong CX, Li YC, Shen SX, Zhao ZH, Liang L, Dong GP, Yan CY, Du HW.
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
    [Abstract] [Full Text] [Related]

  • 2. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment.
    Feigerlová E, Diene G, Oliver I, Gennero I, Salles JP, Arnaud C, Tauber M.
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543
    [Abstract] [Full Text] [Related]

  • 3. Circulating IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 Molar Ratio Concentration and Height Outcome in Prepubertal Short Children on rhGH Treatment over Two Years of Therapy.
    Ballerini MG, Braslavsky D, Scaglia PA, Keselman A, Rodríguez ME, Martínez A, Freire AV, Domené HM, Jasper HG, Bergadá I, Ropelato MG.
    Horm Res Paediatr; 2017 Oct; 88(5):354-363. PubMed ID: 28926833
    [Abstract] [Full Text] [Related]

  • 4. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
    Ranke MB, Traunecker R, Martin DD, Schweizer R, Schwarze CP, Wollmann HA, Binder G.
    Horm Res; 2005 Oct; 64(2):68-76. PubMed ID: 16113581
    [Abstract] [Full Text] [Related]

  • 5. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
    Boguszewski M, Jansson C, Rosberg S, Albertsson-Wikland K.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
    [Abstract] [Full Text] [Related]

  • 6. The -202 A allele of insulin-like growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with severe growth hormone deficiency.
    Costalonga EF, Antonini SR, Guerra-Junior G, Mendonca BB, Arnhold IJ, Jorge AA.
    J Clin Endocrinol Metab; 2009 Feb; 94(2):588-95. PubMed ID: 18984657
    [Abstract] [Full Text] [Related]

  • 7. Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth.
    Tillmann V, Patel L, Gill MS, Whatmore AJ, Price DA, Kibirige MS, Wales JK, Clayton PE.
    Clin Endocrinol (Oxf); 2000 Sep; 53(3):329-36. PubMed ID: 10971450
    [Abstract] [Full Text] [Related]

  • 8. Diagnosis and growth hormone (GH) therapy in children with GH deficiency: experience in King Chulalongkorn Memorial Hospital, Thailand.
    Wacharasindhu S, Supornsilchai V, Aroonparkmongkol S, Srivuthana S.
    J Med Assoc Thai; 2007 Oct; 90(10):2047-52. PubMed ID: 18041422
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of Safety and Efficacy of Growth Hormone Therapy by IGF-1 Z Score in Children with Short Stature.
    Liu HJ, Wang LH, Chen L.
    Adv Ther; 2019 Sep; 36(9):2374-2383. PubMed ID: 31301056
    [Abstract] [Full Text] [Related]

  • 10. Acromegalic features in growth hormone (GH)-deficient patients after long-term GH therapy.
    Carvalho LR, de Faria ME, Osorio MG, Estefan V, Jorge AA, Arnhold IJ, Mendonca BB.
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):788-92. PubMed ID: 14974923
    [Abstract] [Full Text] [Related]

  • 11. Measurement of IGF-1, IGFBP-3 and free IGF-1 levels by ELISA in growth hormone (GH) deficient children before and after GH replacement.
    Wacharasindhu S, Aroonparkmongkol S, Srivuthana S.
    Asian Pac J Allergy Immunol; 2002 Sep; 20(3):155-60. PubMed ID: 12587838
    [Abstract] [Full Text] [Related]

  • 12. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
    Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Allen L, Rosenfeld RG.
    J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
    [Abstract] [Full Text] [Related]

  • 13. Short stature associated with high circulating insulin-like growth factor (IGF)-binding protein-1 and low circulating IGF-II: effect of growth hormone therapy.
    Barreca A, Bozzola M, Cesarone A, Steenbergh PH, Holthuizen PE, Severi F, Giordano G, Minuto F.
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3534-41. PubMed ID: 9768660
    [Abstract] [Full Text] [Related]

  • 14. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.
    Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J.
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3653-60. PubMed ID: 11061518
    [Abstract] [Full Text] [Related]

  • 15. Recombinant human growth hormone plus recombinant human insulin-like growth factor-1 coadministration therapy in short children with low insulin-like growth factor-1 and growth hormone sufficiency: results from a randomized, multicenter, open-label, parallel-group, active treatment-controlled trial.
    Backeljauw PF, Miller BS, Dutailly P, Houchard A, Lawson E, Hale DE, Reiner B, Sperling MA, MS316 Study Group.
    Horm Res Paediatr; 2015 Oct; 83(4):268-79. PubMed ID: 25765099
    [Abstract] [Full Text] [Related]

  • 16. Is insulin-like growth factor-1 monitoring useful in assessing the response to growth hormone of growth hormone-deficient children?
    Lanes R, Jakubowicz S.
    J Pediatr; 2002 Nov; 141(5):606-10. PubMed ID: 12410186
    [Abstract] [Full Text] [Related]

  • 17. Growth hormone therapy does not alter the insulin-like growth factor-I/insulin-like growth factor binding protein-3 molar ratio in growth hormone-deficient children.
    Scirè G, Del Bianco C, Spadoni GL, Cianfarani S.
    J Endocrinol Invest; 2008 Feb; 31(2):153-8. PubMed ID: 18362507
    [Abstract] [Full Text] [Related]

  • 18. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial.
    Battelino T, Rasmussen MH, De Schepper J, Zuckerman-Levin N, Gucev Z, Sävendahl L, NN8640-4042 Study Group.
    Clin Endocrinol (Oxf); 2017 Oct; 87(4):350-358. PubMed ID: 28656605
    [Abstract] [Full Text] [Related]

  • 19. Growth response to rhIGF-I 80 microg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype.
    Azcona C, Preece MA, Rose SJ, Fraser N, Rappaport R, Ranke MB, Savage MO.
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):787-92. PubMed ID: 10619985
    [Abstract] [Full Text] [Related]

  • 20. GH response to provocation and circulating IGF-I and IGF-binding protein-3 concentrations, the IGF-I generation test and clinical response to GH therapy in children with beta-thalassaemia.
    Soliman AT, El Banna N, Ansari BM.
    Eur J Endocrinol; 1998 Apr; 138(4):394-400. PubMed ID: 9578506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 132.